| http://www.w3.org/ns/prov#value | - In certain situations, it may be desirable to use gene therapy methods for administration of TRIP1 or TP2 to patients suffering from HIV infection, AIDS, or other diseases for which TRIP1 or TP2 is a viable therapeutic agent, such as, for example, premature aging and other aging disorders.
|
